Actively Recruiting
Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Led by University Hospital, Essen · Updated on 2025-09-04
25
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
CONDITIONS
Official Title
Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 40 years
- Diagnosed with amyloidosis (ATTR or AL type)
- Women must have a negative pregnancy test within weeks before imaging
You will not qualify if you...
- Receiving amyloidosis-specific treatment before study inclusion
- Participating in other clinical trials for amyloidosis treatment
- Pregnant
- Contraindications for MRI such as eGFR below 30 ml/min/1.73m2, gadolinium allergy, or unsuitable metallic implants/devices for 3T MRI
- Unable to provide consent
- Refusal to consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nuclear medicine, University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147
Actively Recruiting
Research Team
D
David Kersting, MD, PhD
CONTACT
L
Lukas Kessler, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here